Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2a Safety and Pharmacokinetic Study of Trilaciclib (G1T28) with Topotecan in Previously Treated Extensive-Stage Small Cell Lung Cancer
2016-004611-13Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by G1 Therapeutics, Inc. Primary endpoints: Safety and tolerability of trilaciclib (G1T28) combined with topotecan and Effect of trilaciclib (G1T28) on chemotherapy-induced myelosuppression. Started Feb 2017; status: completed.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-004611-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004611-13.